By Stephen Nakrosis

The Janssen Pharmaceutical Cos. of Johnson & Johnson said Friday the U.S. Food and Drug Administration granted Breakthrough Therapy Designation for JNJ-68284528, an investigational therapy to treat certain myeloma patients.

Janssen said the designation was supported by results from its Phase 1b/2 CARTITUDE-1 study, a multicenter clinical trial evaluating the safety and efficacy of JNJ-4528 currently active in the U.S.

"The primary objective of the Phase 1b portion of the study is to characterize the safety of JNJ-4528 and confirm the dose for future clinical trials," the company said.

--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

(END) Dow Jones Newswires

December 06, 2019 16:48 ET (21:48 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Johnson and Johnson (NYSE:JNJ)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024 Plus de graphiques de la Bourse Johnson and Johnson
Johnson and Johnson (NYSE:JNJ)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024 Plus de graphiques de la Bourse Johnson and Johnson